The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

BACKGROUND: The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who wer...

Descripción completa

Detalles Bibliográficos
Autores principales: DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, Pappo, Alberto S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263791/
https://www.ncbi.nlm.nih.gov/pubmed/30204247
http://dx.doi.org/10.1002/cncr.31701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263791/
https://www.ncbi.nlm.nih.gov/pubmed/30204247
http://dx.doi.org/10.1002/cncr.31701

Ejemplares similares